Indeed, the SURPASS-CVOT study, which compares tirzepatide head-to-head with dulaglutide, will likely provide more comprehensive answers (expected by the end of 2024)
2024 Oct 15;44(11):NP809-NP818 Functional and Aesthetic Periorbital, Ocular Adnexal and Ocular Surface Changes Linked to GLP-1 Receptor Agonists
See individual service pages for full pricing details
Sustainable weight loss rarely happens on a timeline like that, especially without lifestyle changes
In summary, tirzepatide achieved more pronounced HbA1c reductions with a lower incidence of hypoglycemia at week 52 compared to insulin glargine
9 In August 2023, the ASA published the first set of guidelines for consideration in patients taking GLP-1 receptor agonists prior to a scheduled elective procedures 9 : - For patients on daily, typically oral, dosed GLP-1 receptor agonists, consider holding their dose on the day of the procedure